The present application relates to a compound of Chemical Formula 1 and an organic light emitting device including the same.

The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula:

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula:

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

This disclosure relates to trans-cyclooctene compounds and methods of using the same in bioorthogonal labeling experiments.

This disclosure relates to trans-cyclooctene compounds and methods of using the same in bioorthogonal labeling experiments.

The present application relates to a compound of Chemical Formula 1 and an organic light emitting device including the same: ##STR00001## wherein Ar.sub.1 to Ar.sub.3, L.sub.1 and L.sub.2 are described herein.

The present application relates to a compound of Chemical Formula 1 and an organic light emitting device including the same: ##STR00001## wherein Ar.sub.1 to Ar.sub.3, L.sub.1 and L.sub.2 are described herein.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.